Skip to main content
AIM ImmunoTech Inc. logo

AIM ImmunoTech Inc. — Investor Relations & Filings

Ticker · AIM ISIN · US42366C3016 US Professional, scientific and technical activities
Filings indexed 1,091 across all filing types
Latest filing 2025-04-23 Director's Dealing
Country US United States of America
Listing US AIM

About AIM ImmunoTech Inc.

https://aimimmuno.com/

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics for various diseases. The company's primary areas of focus include oncology, immune disorders, and viral diseases. Its lead drug candidate is Ampligen® (rintatolimod), a proprietary immuno-modulator with broad-spectrum activity demonstrated in pre-clinical testing. Ampligen® is being evaluated in multiple clinical studies for a range of debilitating and life-threatening conditions.

Recent filings

Filing Released Lang Actions
Director's Dealing 2025
Director's Dealing
2025-04-23 English
Director's Dealing 2025
Director's Dealing
2025-04-23 English
Director's Dealing 2025
Director's Dealing
2025-04-23 English
Director's Dealing 2025
Director's Dealing
2025-04-07 English
Delisting Announcement 2025
Delisting Announcement Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The key content is the notice of delisting of AIM ImmunoTech Inc.'s common stock from the NYSE American due to low selling price, including details about the suspension of trading and the company's right to appeal. The document also includes a press release as an exhibit discussing the delisting. There are no financial statements or detailed financial data presented, and the document is focused on the delisting event. According to the filing definitions, this matches the category of a Delisting Announcement (DLST). The document length is over 6,000 characters, so it is not a mere announcement of a report publication but the actual filing of the delisting event. Therefore, the correct classification is DLST with high confidence.
2025-04-04 English
Director's Dealing 2025
Director's Dealing
2025-04-04 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.